Diagnostic and Prognostic Value of hsa_piR_022710, hsa_piR_019822, and hsa_piR_020840 in Early-Stage Non-Small-Cell Lung Cancer : Implications for Recurrence and Survival in Squamous Cell Carcinoma Patients
He, Y. (Chengdu University)
Altuna-Coy, A. (Universitat de Barcelona)
Acosta-Plasencia, M. (Universitat de Barcelona)
Molins, Laureano (Hospital Clínic i Provincial de Barcelona)
Sánchez Lorente, David (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Martinez, Daniel (Hospital Clínic i Provincial de Barcelona)
Díaz, T. (Universitat de Barcelona)
Na, R. (Universitat de Barcelona)
Marrades, Ramón M. (Hospital Clínic i Provincial de Barcelona)
Navarro, Alfons (Hospital Clínic i Provincial de Barcelona)
Universitat Autònoma de Barcelona

Fecha:	2025
Resumen:	Despite significant advancements in early detection and treatment, non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality. Specifically, in early-stage cases, recurrence after surgery continues to be the principal cause of death for these patients. The urgent need for novel diagnostic and prognostic biomarkers has directed attention towards PIWI-interacting RNAs (piRNAs), a group of small RNAs that regulate genomic stability and epigenetics. Some piRNAs, including hsa_piR_022710, hsa_piR_019822, and hsa_piR_020840, have been described as deregulated in various cancers. This study investigated the expression of these three piRNAs by RT-qPCR in 277 NSCLC patients and developed survival and CART classification models to predict recurrence risk, overall survival (OS), and disease-free survival (DFS). hsa_piR_019822 and hsa_piR_020840 were able to discriminate between tumor and normal tissue, as well as between adenocarcinoma and squamous cell carcinoma (LUSC) patients. Elevated expression of hsa_piR_019822 and hsa_piR_022710 was correlated with an increased risk of recurrence and poorer DFS and OS in LUSC patients. Patients with high hsa_piR_022710 expression more greatly benefited from adjuvant treatment. In summary, higher piRNA levels were associated with an increased risk of recurrence and poorer survival outcomes, especially in LUSC patients, where they may help guide personalized treatment strategies.
Ayudas:	Agencia Estatal de Investigación SAF2017-88606-P
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	NSCLC ; Biomarkers ; PiRNA ; Prognosis ; Recurrence ; Squamous cell carcinoma
Publicado en:	International journal of molecular sciences, Vol. 26 Núm. 7 (april 2025) , p. 2870, ISSN 1422-0067

DOI: 10.3390/ijms26072870
PMID: 40243460

18 p, 5.9 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Instituto de Investigación e Innovación Parc Taulí (I3PT)
Artículos > Artículos de investigación
Artículos > Artículos publicados